Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 27Terminated 8Unknown 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Breast 2Sarcoma 1Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Dermatologic 1

Conditions

Waldenstrom Macroglobulinemia 1Skin Neoplasms 1Neoplasms, Plasma Cell 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1

Interventions

Cyclophosphamide 30Rituximab 23zanubrutinib 18fludarabine 14Vincristine 14venetoclax 13Prednisone 13blinatumomab 12Magnetic Resonance Spectroscopy 12Specimen Handling 11Doxorubicin 11obinutuzumab 10Bendamustine Hydrochloride 10Lenalidomide 9Dexamethasone 8polatuzumab vedotin 7glofitamab 7Methotrexate 7Radiotherapy 6Prednisolone 6N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 6Cytarabine 6Biopsy 6pirtobrutinib 5pegaspargase 5Immunotherapy, Adoptive 5tislelizumab 4tafasitamab 4selinexor 4orelabrutinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Everolimus × Lymphoid × Clear all
NCT07426484 2026-02-23

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

Dana-Farber Cancer Institute

Phase 4 Not yet recruiting
80 enrolled
DermatologicLymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Waldenstrom Macroglobulinemia, Skin Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡